Patents Assigned to Ocata Therapeutics, Inc.
  • Publication number: 20170152481
    Abstract: Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom.
    Type: Application
    Filed: July 6, 2016
    Publication date: June 1, 2017
    Applicant: Ocata Therapeutics, Inc.
    Inventors: Robert Lanza, Shi-Jiang Lu
  • Publication number: 20170121681
    Abstract: Methods for generating enucleated erythroid cells using pluripotent stem cells are provided. The methods permit the production of large numbers of cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Methods for generating megakaryocyte and platelets are also provided.
    Type: Application
    Filed: March 24, 2016
    Publication date: May 4, 2017
    Applicant: Ocata Therapeutics, Inc.
    Inventors: Robert Lanza, Shi-Jiang Lu
  • Patent number: 9410123
    Abstract: Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: August 9, 2016
    Assignee: Ocata Therapeutics, Inc.
    Inventors: Robert Lanza, Shi-Jiang Lu
  • Publication number: 20160175362
    Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.
    Type: Application
    Filed: September 17, 2015
    Publication date: June 23, 2016
    Applicant: Ocata Therapeutics, Inc.
    Inventors: Robert P. Lanza, Shi-Jiang Lu, Wei Wang
  • Publication number: 20160115450
    Abstract: Methods of generating and expanding human hemangio-colony forming cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications.
    Type: Application
    Filed: September 29, 2015
    Publication date: April 28, 2016
    Applicant: OCATA THERAPEUTICS, INC.
    Inventors: Robert Lanza, Shi-Jiang Lu
  • Publication number: 20160030490
    Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicant: Ocata Therapeutics, Inc.
    Inventors: Robert P. Lanza, Shi-Jiang Lu, Wei Wang
  • Publication number: 20150366915
    Abstract: This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant site in both patients, with subsequent evidence the cells had attached and integrated into the native RPE layer. No signs of inflammation or hyperproliferation were observed. The hESC-derived RPE cells have shown no signs of rejection or tumorigenicity at the time of this report. Visual measurements suggest improvement in both patients.
    Type: Application
    Filed: May 15, 2015
    Publication date: December 24, 2015
    Applicant: Ocata Therapeutics, Inc.
    Inventors: Roger Gay, Irina V. Klimanskaya, Robert P. Lanza
  • Patent number: 9193950
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: November 24, 2015
    Assignee: Ocata Therapeutics, Inc.
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Publication number: 20150328261
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Application
    Filed: April 21, 2015
    Publication date: November 19, 2015
    Applicant: Ocata Therapeutics, Inc.
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Patent number: 9181524
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: November 10, 2015
    Assignee: Ocata Therapeutics, Inc.
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Publication number: 20150313944
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Application
    Filed: December 21, 2013
    Publication date: November 5, 2015
    Applicant: Ocata Therapeutics, Inc.
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Publication number: 20150272994
    Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.
    Type: Application
    Filed: February 23, 2015
    Publication date: October 1, 2015
    Applicant: Ocata Therapeutics, Inc.
    Inventors: Erin Anne Kimbrel, Robert P. Lanza, Jianlin Chu, Nicholas Arthur Kouris
  • Publication number: 20150209126
    Abstract: Methods for generating embryos using pluripotent stem cells are provided. The subject methods include methods for generating chimeric embryos, wherein only a subset of the cells of each embryo are genetically identical to the pluripotent stem cells used in the generation process. The subject methods also include methods for generating embryos that are identical or are essentially genetic clones of the pluripotent stem cells (e.g., the resulting embryos are substantially identical, genetically, to the pluripotent stem cells used in the generation process).
    Type: Application
    Filed: April 9, 2015
    Publication date: July 30, 2015
    Applicant: Ocata Therapeutics, Inc.
    Inventor: Robert P. LANZA
  • Patent number: 9080150
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: July 14, 2015
    Assignee: Ocata Therapeutics, Inc.
    Inventors: Irina V. Klimanskaya, Robert Lanza
  • Patent number: 9045732
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: June 2, 2015
    Assignee: Ocata Therapeutics, Inc.
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Patent number: 9040770
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: May 26, 2015
    Assignee: Ocata Therapeutics, Inc.
    Inventors: Irina Klimanskaya, Robert Lanza
  • Patent number: 9040038
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: May 26, 2015
    Assignee: Ocata Therapeutics, Inc.
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Patent number: 9040039
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: May 26, 2015
    Assignee: Ocata Therapeutics, Inc.
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Patent number: 8962321
    Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: February 24, 2015
    Assignee: Ocata Therapeutics, Inc.
    Inventors: Erin Anne Kimbrel, Robert Lanza, Jianlin Chu, Nicholas Arthur Kouris
  • Patent number: 8961956
    Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: February 24, 2015
    Assignee: Ocata Therapeutics, Inc.
    Inventors: Erin Anne Kimbrel, Robert Lanza, Jianlin Chu, Nicholas Arthur Kouris